Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma

被引：0
|
作者：
Tomohiko Kamimura
Toshihiro Miyamoto
Shuichiro Takashima
Noriko Yokota
Yong Chong
Yoshikiyo Ito
Koichi Akashi
机构：
[1] Harasanshin Hospital,Department of Hematology
[2] Kyushu University,Department of Medicine and Biosystemic Science, Graduate School of Medical Science
[3] Harasanshin Hospital,Department of Nursing
来源：
International Journal of Hematology | 2012年 / 96卷
关键词：
Multiple Myeloma; Bortezomib; Japanese Patient; Subcutaneous Administration; Injection Site Reaction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：525 / 527
页数：2
相关论文
共 50 条
  • [31] BLOOD DISTRIBUTION OF SUBCUTANEOUS BORTEZOMIB AND ITS KINETICS IN MULTIPLE MYELOMA PATIENTS
    Osawa, Takashi
    Naito, Takafumi
    Mino, Yasuaki
    Kawakami, Junichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S89 - S89
  • [32] Efficacy and safety study of subcutaneous injection of bortezomib in the treatment of de novopatients with multiple myeloma
    刘辉
    China Medical Abstracts (Internal Medicine), 2013, 30 (04) : 229 - 230
  • [33] RETROSPECTIVE STUDY OF THE EFFICACY, ECONOMY AND SAFETY OF TREATMENT WITH SUBCUTANEOUS INJECTION OF BORTEZOMIB IN DE NOVO PATIENTS WITH MULTIPLE MYELOMA
    Yan, S.
    Wang, P.
    Xu, Y.
    Zheng, H.
    Ma, L.
    Jin, S.
    Fu, C.
    Wu, D.
    HAEMATOLOGICA, 2016, 101 : 801 - 802
  • [34] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Evangelos Terpos
    Marianna Politou
    Amin Rahemtulla
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 623 - 625
  • [35] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Terpos, E
    Politou, M
    Rahemtulla, A
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (10) : 623 - 625
  • [36] Subcutaneous Bortezomib, Melphalan and Prednisone in Elderly Newly Diagnosed Multiple Myeloma Patients
    Herbaux, Charles
    Joao, Cristina M.
    Plocque, Alexia
    Richez, Valentine
    Gay, Francesca
    Renaud, Loic
    Legros, Laurence
    Garderet, Laurent
    Ikhlef, Souhila
    Pegourie, Brigitte
    Escoffre-Barbe, Martine
    Royer, Bruno
    Voillat, Laurent
    Hulin, Cyrille
    Banos, Anne
    Voog, Eric G.
    Karlin, Lionel
    Stoppa, Anne-Marie
    Benboubker, Lotfi
    Zweegman, Sonja
    De Jongh, Eva
    Abildgaard, Niels
    Le Du, Katell
    Jurczyszyn, Artur J.
    Moreau, Philippe
    Facon, Thierry
    Caillot, Denis
    Terpos, Evangelos
    Leleu, Xavier
    BLOOD, 2014, 124 (21)
  • [37] Subcutaneous Bortezomib in Older Multiple Myeloma Patients (> 75 y/o)
    Martinez Robles, Violeta
    Ballina, Belen
    Cerda, Seila
    Gonzalez, Paola
    Rodon, Filomeno
    de las Heras, Natalia
    Antonio Rodriguez-Garcia, Jose
    Escalante, Fernando
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E103 - E103
  • [38] Audit into the prevalence of injection site reaction following subcutaneous administration of adalimumab
    Lloyd-Ford, G.
    Goel, V.
    Lewis, A.
    Hook, L.
    Taylor, S.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S447 - S447
  • [39] Subcutaneous Injection Of Bortezomib, Combined With Doxorubicin and Dexamethasone (sPAD) Is Effective and Safety Induction Therapy For Untreated Multiple Myeloma Patients
    Takezako, Naoki
    Sekiguchi, Naohiro
    Nagata, Akihisa
    Hagino, Tsuyoshi
    Noto, Satoshi
    Natori, Kazuhiko
    Miwa, Akiyoshi
    BLOOD, 2013, 122 (21)
  • [40] Outcomes of patients with multiple myeloma refractory to different administration schedules of bortezomib
    Goel, Utkarsh
    Charalampous, Charalampos
    Kapoor, Prashant
    Binder, Moritz
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Fonder, Amie L.
    Gertz, Morie A.
    Gonsalves, Wilson I.
    Hayman, Suzanne R.
    Hobbs, Miriam A.
    Hwa, Yi Lisa
    Kourelis, Taxiarchis
    Lacy, Martha
    Leung, Nelson
    Lin, Yi
    Warsame, Rahma M.
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345